There is currently no biosimilar competition in sight for around one third of the European high-sales biologics that will lose their exclusivity until 2032. Meike Madelung from IQVIA presented these and other interesting aspects of the perspectives for biosimilars in Europe at the very informative IQVIA Roundtable in Frankfurt today.